Like many students at Alexandria Senior High School, Amera Awawda, Thamina Jabbar and Sarah Wilson are proud of the Trojan ...

Incorporated announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective CDK9 inhibitor, as monotherapy ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...

Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational ...

Rallybio Corporation , a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the ...

Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from an ongoing Phase 1/2 ...

In single-ascending dose study in VWD patients, a subcutaneous dose of VGA039 was associated with substantial reductions in bleeds ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations at the American Society of Hematology Annual ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation an ...

(Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera ...